#1 Clinical Trials Search in Europe

Cefotaxime

Cefotaxime, a third-generation cephalosporin antibiotic, has been the subject of several clinical trials investigating its efficacy in treating various infections. These studies have explored its use in conditions such as spontaneous bacterial peritonitis, urinary tract infections, and its impact on intestinal microbiota. The trials have compared cefotaxime to other antibiotics and examined different administration methods to optimize its effectiveness while minimizing potential side effects.

Table of Contents

What is Cefotaxime?

Cefotaxime is an antibiotic medication that belongs to a class of drugs called third-generation cephalosporins. It’s also known by brand names such as Claforan and Cefotax[1]. This medication is used to treat various bacterial infections and is typically administered intravenously (through a vein) in hospital settings.

Uses of Cefotaxime

Cefotaxime is prescribed for several types of infections, including:

  • Urinary Tract Infections (UTIs): Particularly for severe cases known as pyelonephritis, which is an infection of the kidneys[2].
  • Spontaneous Bacterial Peritonitis (SBP): An infection of the abdominal cavity fluid in patients with liver disease[3].
  • Febrile Urinary Tract Infections: UTIs accompanied by fever[2].
  • Other bacterial infections: Including those caused by certain types of bacteria resistant to other antibiotics[4].

How Cefotaxime Works

Cefotaxime works by interfering with the cell wall formation of bacteria. Specifically, it targets proteins called penicillin-binding proteins (PBPs) that are essential for bacterial cell wall synthesis. By binding to these proteins, cefotaxime prevents the bacteria from forming a proper cell wall, leading to their death[5].

Administration and Dosage

Cefotaxime is typically administered in hospital settings through intravenous (IV) injection. The dosage can vary depending on the type and severity of the infection, as well as other patient factors. Some common dosing regimens include:

  • 1-2 grams every 6-8 hours for severe infections[5].
  • 2 grams every 8 hours for certain types of infections[6].
  • 1 gram every 8 hours for less severe infections[1].

The duration of treatment typically ranges from 5 to 10 days, depending on the infection being treated and the patient’s response to the medication[2].

Effectiveness and Research

Cefotaxime has been the subject of numerous clinical trials to evaluate its effectiveness in treating various infections. Some key findings include:

  • It has shown effectiveness in treating urinary tract infections, including those caused by certain antibiotic-resistant bacteria[2].
  • Research is ongoing to compare its effectiveness to other antibiotics in treating spontaneous bacterial peritonitis[7].
  • Studies are investigating its impact on the intestinal microbiota (the community of microorganisms in the gut) compared to other antibiotics[1].

Side Effects and Considerations

Like all medications, cefotaxime can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea
  • Rash
  • Pain or inflammation at the injection site

More serious side effects, though rare, can include severe allergic reactions and effects on blood cell counts. It’s important to inform your healthcare provider of any side effects you experience[2].

Additionally, the use of cefotaxime may lead to changes in the normal bacteria of the colon and may permit overgrowth of certain types of bacteria. This is being studied to understand its long-term impacts[1].

Alternatives and Comparisons

While cefotaxime is an effective antibiotic, there are other options that may be considered depending on the specific infection and patient factors:

  • Ceftriaxone: Another third-generation cephalosporin that is sometimes used as an alternative to cefotaxime. Some studies are comparing their effects on intestinal bacteria[1].
  • Meropenem: A different class of antibiotic (carbapenem) that is being compared to cefotaxime for treating spontaneous bacterial peritonitis[8].
  • Gemifloxacin: An oral antibiotic that is being studied as a potential alternative to intravenous cefotaxime for certain infections[7].

The choice between these antibiotics depends on factors such as the type of infection, the bacteria causing the infection, and individual patient characteristics. Your healthcare provider will determine the most appropriate antibiotic for your specific situation.

Aspect Details
Primary Uses in Trials Treatment of spontaneous bacterial peritonitis, urinary tract infections, study of antibiotic resistance
Administration Methods Intravenous infusion, typically 1-2 grams every 8-12 hours
Comparison Drugs Meropenem, ceftriaxone, gemifloxacin
Treatment Duration Generally 3-10 days, depending on the infection and study protocol
Key Outcome Measures Clinical cure rates, bacteriological response, impact on antibiotic-resistant bacteria
Safety Considerations Monitoring for adverse events, impact on intestinal microbiota
Emerging Research Areas Effects on intestinal microbiota, optimizing dosing strategies, combating antibiotic resistance

FAQ

  • What is cefotaxime used for in clinical trials? Cefotaxime is being studied for treating various infections, including spontaneous bacterial peritonitis, urinary tract infections, and its impact on intestinal bacteria resistant to antibiotics.
  • How is cefotaxime typically administered in these trials? Cefotaxime is usually administered intravenously, with dosages ranging from 1 to 2 grams every 8 to 12 hours, depending on the specific trial and condition being treated.
  • What are some of the comparator drugs used alongside cefotaxime in clinical trials? Some trials compare cefotaxime to other antibiotics such as meropenem, ceftriaxone, and gemifloxacin to evaluate its relative effectiveness in treating various infections.
  • What are researchers looking at regarding cefotaxime's impact on intestinal bacteria? Researchers are studying how cefotaxime affects the emergence of antibiotic-resistant bacteria in the intestinal microbiota, comparing it to other antibiotics like ceftriaxone.
  • How long do typical treatment courses with cefotaxime last in these trials? Treatment durations in the trials vary, but they generally range from 3 to 10 days, depending on the specific infection being treated and the study protocol.

Ongoing Clinical Trials on Cefotaxime

  • Study of pivmecillinam compared to standard antibiotics for treating Escherichia coli urinary tract infection with fever

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway Sweden

  • Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium The Netherlands

  • Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Optimizing Initial Dosing of Flucloxacillin and Drug Combination for Critically Ill Patients with Sepsis in the ICU

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Reducing Antibiotic Use in Severe COPD Exacerbation with Amoxicillin, Cefotaxime, and Ciprofloxacin for Patients on Mechanical Ventilation or Oxygen Therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Customized Antibiotic Treatment Duration for Hospitalized Patients with Community-Acquired Pneumonia Using Cefotaxime and Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Oral Antibiotics Moxifloxacin, Linezolid, and Metronidazole for Patients with Bacterial Brain Abscess

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France The Netherlands Sweden

  • Study on Shortened Antibiotic Treatment for Infectious Endocarditis Using Vancomycin, Meropenem, and Ceftriaxone for Patients with Left-Sided Heart Infection

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Spontaneous bacterial peritonitis (SBP): A serious infection of the abdominal cavity fluid (ascites) in patients with advanced liver disease, often requiring prompt antibiotic treatment.
  • Third-generation cephalosporin: A class of antibiotics that includes cefotaxime, known for their broad-spectrum activity against many types of bacteria.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Empirical treatment: Treatment based on clinical experience and observation rather than confirmed laboratory results, often used in urgent infectious situations.
  • Enterobacteriaceae: A large family of bacteria that includes many common pathogens, some of which can develop resistance to antibiotics.
  • Microbiota: The community of microorganisms living in a specific environment, such as the human gut.
  • Antibiotic resistance: The ability of bacteria to survive exposure to antibiotics that would normally kill them or stop their growth.
  • Polymorphonuclear cells (PMN): A type of white blood cell with a lobed nucleus, important in the immune response to infections.
  • Minimal inhibitory concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • Area under the curve (AUC): A measure used in pharmacology to represent the total drug exposure over time.

References

  1. https://clinicaltrials.gov/study/NCT02659033
  2. https://clinicaltrials.gov/study/NCT02959957
  3. https://clinicaltrials.gov/study/NCT02388035
  4. https://clinicaltrials.gov/study/NCT03922919
  5. https://clinicaltrials.gov/study/NCT00187655
  6. https://clinicaltrials.gov/study/NCT02443285
  7. https://clinicaltrials.gov/study/NCT04168099
  8. https://clinicaltrials.gov/study/NCT05427747